Clinical Trials Logo

Colo-rectal Cancer clinical trials

View clinical trials related to Colo-rectal Cancer.

Filter by:

NCT ID: NCT06218888 Not yet recruiting - Colo-rectal Cancer Clinical Trials

A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Microsatellite Stabilized (MSS/pMMR) Colorectal Cancer With Liver Metastases

Start date: June 1, 2024
Phase: Phase 2
Study type: Interventional

To explore the Efficacy and Safety of Tislelizumab combined with fruquintinib and Chidamide in the treatment of unresectable or advanced microsatellite stabilized (MSS/pMMR) colorectal cancer with liver metastases

NCT ID: NCT06149923 Not yet recruiting - Gastric Cancer Clinical Trials

Association Between ABO Polymorphism and Gastric/Colorectal Cancers

Start date: December 1, 2023
Phase:
Study type: Observational

To assess ABO gene polymorphism (rs8176746) in the patients histopathologically confirmed gastric and/or colorectal cancers relative to healthy controls by real time PCR.

NCT ID: NCT06091592 Completed - Colo-rectal Cancer Clinical Trials

The dıagnostıc Value of Serum autotaxın Level ın Colorectal Cancer

Start date: December 30, 2020
Phase:
Study type: Observational

Colorectal cancer is one of the most common causes of cancer-related death. Early diagnosis is extremely important in terms of treatment and mortality. In this study, we investigated the diagnostic value of serum autotaxin levels in colorectal cancer.

NCT ID: NCT06024837 Recruiting - Colo-rectal Cancer Clinical Trials

Performance of Spectral CT-scan in Patients With Metastatic Colorectal Cancer: a Prospective Multicentre Study

Start date: June 7, 2023
Phase:
Study type: Observational

Spectral CT is a rapidly expanding imaging modality that allows a reduction in iodine dose and irradiation compared to conventional scanning. It uses the difference in attenuation of the material according to the two different energy levels of the incident x-ray beams. The dual-energy scanner has a wide range of clinical applications, particularly in abdominal imaging.

NCT ID: NCT06011772 Recruiting - Colo-rectal Cancer Clinical Trials

EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer

Start date: December 4, 2023
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to determine the immunogenicity of the CIMAvaxEGF® vaccine (that is, its effectiveness in inducing an anti-tumor immune response) in patients with metastatic KRAS/NRAS/BRAF wild-type gene colorectal cancer, when given in combination with standard therapies used in the treatment of advanced colorectal cancer.

NCT ID: NCT05978349 Recruiting - Colo-rectal Cancer Clinical Trials

PTC Drug Sensitivity Detection to Guide Postoperative Adjuvant of Colorectal Cancer

Start date: February 14, 2022
Phase: N/A
Study type: Interventional

The research objectives is to compare vitro 3D drug sensitivity test results of micro tumor (PTC) with the clinical outcomes of patients, evaluate the consistency between the test results of the technology platform and the clinical prognosis, and explore the decision-making value and guiding significance of this technology in assisting the precise treatment of colorectal cancer. The completion of this study will provide real-world data support for the clinical application of micro tumor (PTC) in vitro 3D drug sensitivity detection technology, and provide more valuable reference basis for realizing the individualization and accuracy of colorectal cancer treatment and improving the clinical benefit rate.

NCT ID: NCT05877456 Enrolling by invitation - Colo-rectal Cancer Clinical Trials

Validation of the Global Polypectomy Assessment Tool (GPAT)

GPAT
Start date: March 1, 2023
Phase:
Study type: Observational

Colorectal polypectomy is offten incompletely performed with high variability between endoscopists, resulting in interval cancer or repeated procedures. Current available scoring systems for polypectomy technique are lacking in different areas so the investigators developed the Global Polypectomy Assessment Tool (GPAT) which is an online video-based assessment tool for any colorectal polypectomy. The goal of the study is to assess the validity of GPAT through demonstrating the inter-rater agreement (Fleiss Kappa (κ)). GPAT has 20 items, contains evidence-based statements to aid interpretation, calculates an overall quality score and a complexity score.

NCT ID: NCT05870332 Recruiting - Colo-rectal Cancer Clinical Trials

Nationwide Study of Artificial Intelligence in Adenoma Detection for Colonoscopy

NAIAD
Start date: October 16, 2023
Phase:
Study type: Observational

The goal of this trial is to determine whether use of a Computer Assisted Detection (CADe) programme leads to an increase in ADR for either units or individual colonoscopists, independent of setting or expertise

NCT ID: NCT05851235 Recruiting - Colo-rectal Cancer Clinical Trials

Prehabilitation in Geriatric Patients With Colorectal Neoplasia

PIGEON
Start date: March 22, 2023
Phase: N/A
Study type: Interventional

This an interventional, non-pharmacologic study. Prehabilitation is a multidisciplinary preoperative intervention aimed at preventing or reducing functional decline related to surgery and improving perioperative outcomes. The current study is aimed at standardizing a prehabilitation pathway, evaluating its feasibility within the AUSL Romagna in collaboration with the PRIME Centre and the multiple professions that populate the two institutes in the spirit of confirming the beneficial effect of an integrated prehabilitation programme on surgical outcomes. Patients will follow an intensive prehabilitation course before surgery: - Colon cancer patients will do 4 weeks of prehabilitation before surgery. - Rectal cancer patients will do 12 weeks of prehabilitation after neoadjuvant therapy and before surgery. The prehabilitation course is structured around the following aspects: - Frailty assessment and identification of optimisation fields - Optimisation of modifiable factors (anaemia, polypharmacotherapy, smoking, alcoholism, diabetes) - Assessment by an integrative medicine specialist - Nutritional pre-qualification - Cardiovascular, respiratory, motor prehabilitation - Emotional and psychological prehabilitation

NCT ID: NCT05800418 Completed - Clinical trials for Non-small Cell Lung Cancer

Clinical Study to Compare the Pharmacokinetics and Safety of Ramucirumab Injection With Cyramza ® in Healthy Male Volunteers

Start date: November 4, 2019
Phase: Phase 1
Study type: Interventional

Ramucirumab is a biosimilar drug of CYRAMZA® produced by Chiatai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., LTD. It is a vascular endothelial growth factor receptor 2 (VEGFR-2) antagonist. This single-center, randomized, double-blind, single-dose, parallel phase I study of Ramucirumab injection versus Cyramza ® in healthy male volunteers was designed to evaluate the similarities in pharmacokinetics, tolerance, safety and immunogenicity of Ramucirumab and CYRAMZA®.